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The most common indications for THR in very young patients 
aged under 30 years are rheumatoid arthritis (RA), avascular 
necrosis of the femoral head, and developmental dysplasia of 
the hip (Adelani et al. 2013). The incidence of primary THR 
among young patients (30 to 59 years old) has increased annu-
ally in Finland from 9.5 per 100,000 person years in 1980 to 
61 per 100,000 in 2007 (Skyttä et al. 2011). In 2017, over 
1,000 women aged under 55 underwent a primary THR opera-
tion in Finland (open access statistical report of the Finnish 
Arthroplasty Register 2018: National Institute of Health and 
Welfare 2018).
Only a few studies with rather small sample sizes and local 
data have analyzed the effects of delivery and THR on each 
other. None of these studies have reported problems with 
deliveries after THR, and they indicate that THR does not 
majorly affect the mode of delivery (Monaghan et al. 1987, 
Boot et al. 2003, Meldrum et al. 2003, Yazici et al. 2003, 
Sierra et al. 2005, Stea et al. 2007, Smith et al. 2008) Further, 
THR survival is not decreased, and the delivery method does 
not affect THR survival (Meldrum et al. 2003, Sierra et al. 
2005). However, women have reported concerns regarding 
vaginal delivery and fear of delivery positions harming the 
THR (Ostensen 1993, Meldrum et al. 2003, Stea et al. 2007). 
Very young patients seem to have worse clinical out-
comes in terms of pain relief and function after THR, even 
though implant survival rates and radiological outcomes have 
improved (Adelani et al. 2013, Swarup et al. 2017). Clinical 
outcomes may be limited by systemic diseases, such as RA, 
that still comprise the majority of indications for THR in these 
very young patients. The survivorship of the THR is often 
shortened due to the loosening of cup or stem in very young 
patients, men, and patients with a higher BMI (Melloh et al. 
2011). While in some studies underlying diseases have not 
negatively affected the survival of the hip prosthesis (Han-
nouche et al. 2016), dysplastic hips appear to have worse sur-
Background and purpose — Previous small studies have 
suggested that delivery does not adversely affect the sur-
vivorship of total hip replacement (THR). We investigated 
whether delivery after primary THR affects hip implant sur-
vivorship in a large population-based study sample
Patients and methods — In this register-based nation-
wide cohort study, all women aged 15–45 who underwent 
primary THR in Finland from 1987 to 2007 were included 
from the Finnish Arthroplasty Register. Data on deliveries 
were obtained from the medical birth register. After primary 
THR, 111 women (133 THRs) delivered and formed the 
delivery group. In the reference group, 1,878 women (2,343 
THRs) had no deliveries. We used Kaplan–Meier analysis 
with 95% confidence intervals (CI) to study implant survi-
vorship at 6 and 13 years, and Cox multiple regression to 
assess survival and hazard ratios (HRs), with revision for 
any reason as an endpoint with adjustment for age, rheuma-
toid arthritis, and stem and cup fixation.
Results — 51 (38%) revisions were recorded in the deliv-
ery group and 645 (28%) revisions in the reference group. 
The 6-year implant survivorship was 91% (CI 85–96) in 
the delivery group and 88% (CI 87–90) in the reference 
group. The 13-year survival rates were 50% (CI 39–62) and 
61% (CI 59–64). The adjusted HR for revision after deliv-
ery was 0.7 (CI 0.4–1.2) in ≤ 6.8 years’ follow-up and 1.1  
(CI 0.8–1.6) in > 6.8 years’ follow-up.
Interpretation — Based on the findings in this nation-
wide study of hip replacement in fertile-aged women, deliv-
ery does not seem to decrease THR implant survivorship; 
women should not be afraid of or avoid becoming pregnant 
after THR.
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vival rates compared with non-dysplastic hips (Tsukanaka et 
al. 2016). Metal-on-metal (MoM) implants have worse sur-
vival rates compared with non-MoM implants and are since 
2012 are no longer used in Finland due to common adverse 
local tissue reactions that have led to numerous revisions 
(Smith et al. 2012, Furnes et al. 2014, Varnum et al. 2015). 
Because THR implant survival is substantially lower in very 
young patients compared with older patients, THR should 
be considered as the treatment option of last resort for very 
young patients (Swarup et al. 2015, Hannouche et al. 2016). 
We evaluated whether delivery adversely affects the survi-
vorship of THR in a nationwide register-based study sample.
Patients and methods
Data for this nationwide register-based study were gath-
ered from 3 different national registers. Information on all 
women aged 15 to 45 who underwent THR operation in Fin-
land between 1987 and 2007 was obtained from the Finnish 
Arthroplasty Register (FAR). The register is maintained by 
the National Institute for Health and Welfare (THL), and it 
contains information on all orthopedic prostheses operated 
from 1980 in Finland. All the information in the FAR has been 
collected prospectively. The current (2017) completeness of 
the register is 95% for primary THR, and it matches well 
with data from the Finnish Hospital Discharge Register (open 
access statistical report of the Finnish Arthroplasty Register 
2018: NIHW 2018). 
In the present study, the operation day of the primary THR 
was used as the starting point of the follow-up. Because we 
did not have information on primary THR operations before 
1987, a revision THR as the first event in the FAR after Janu-
ary 1, 1987 was an exclusion criterion in the study. Women 
with bilateral prostheses were included, as earlier research 
has shown that this does not bias the results (Lie et al. 2004, 
Ranstam and Robertsson 2010). The endpoint for the follow-
up was either revision, death, emigration, or December 31, 
2007, whichever came first. The outcome was the revision of 
the hip for any reason.
2,012 women with 2,499 primary THRs were selected from 
the register. Of the THRs selected, 23 were excluded due to a 
lack of information on many key variables (Figure 1). 
Information on pregnancies and deliveries was gathered 
from the National Medical Birth Register (MBR) maintained 
by the THL. Pregnancies and deliveries from January 1, 1987 
to December 31, 2007 were included in this study. The MBR 
contains information on all pregnancies of at least 22 gesta-
tional weeks ending in delivery and information on deliveries 
and newborns. MBR data match well with hospital discharge 
data and the coverage of the register has improved over the 
years. If there was no information in the MBR, the woman 
was not considered to have been pregnant. In the study, 
women who had given birth after THR formed the delivery 
group, and women without pregnancy after THR formed the 
reference group. 
The Register for Reimbursable Diseases is maintained by 
the Finnish Social Insurance Institution of Finland. It contains 
information on reimbursable chronic diseases. A medical 
statement written by a certified doctor is needed to gain reim-
bursement for chronic disease. Information on all the reim-
bursements for this study population was obtained. If there 
was no information available, women were considered as not 
having chronic diseases. 
In this study, RA was the most common diagnosis. Other 
chronic diseases were rare, but the following diseases were 
found: asthma, diabetes mellitus type 1, epilepsy, hypothy-
roidism, hypertension, inflammatory bowel disease, and major 
psychiatric disease.
Statistics
Categorized variables were compared by chi-square test between 
the groups and reported as proportions. Continuous variables 
were compared by their distribution. Normally distributed vari-
ables were compared by Student’s t-test and reported by means 
with standard deviations (SD). Non-normally distributed vari-
ables were compared by Mann–Whitney U-test and reported 
by medians with interquartile range. A p-value under 0.05 was 
considered statistically significant in all analyses. Kaplan-Meier 
survival analyses with 95% confidence intervals (CI) were per-
formed to evaluate the survival of the hips in both the delivery 
group and the reference group. Survival rates were calculated 
for 6 years’ and 13 years’ follow-up. The follow-up was con-
tinued until 13 years when 20 THRs were still at risk (life table 
analysis) in the delivery group. The follow-up period was cal-
culated from primary THR until revision THR or until the date 
the patient was censored at the end of the study (December 31, 
2007), or date of emigration, or date of death. The Cox propor-
tional hazards model was used to analyze the effect of potential 
confounders and count hazard ratios (HR). The adjustments 
Figure 1. Flow chart of study population and events of total hip replace-
ment (THR) survival among fertile-aged (15 to 45) women having 
delivery compared with women not having delivery after THR. 
Women aged 15–45
with primary THR 1987–2007
in the Finnish Arthroplasty Register
n = 2,012
Included
n = 1,989
YES     Delivery after THR      NO
Excluded
missing data
n = 23 
Delivery group
111 women
133 THRs
  51 revisions
Reference group
1,878 women
2,343 THRs
   645 revisions
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used in the Cox proportional analysis were the following: age at 
the time of primary THR, RA, stem fixation, and cup fixation. 
Because the proportional hazards assumption was not met in the 
Cox model (crossing survival curves at 6.8 years), the follow-
up was divided into 2 time periods, and a piecewise Cox pro-
portional model was performed. The first follow-up period was 
the time before the crossing at 6.8 years, and the second period 
was from the crossing until the end of the follow-up (6.8–21.0 
years). All the analyses were performed using SPSS statistical 
software version 25.0 (IBM Corp, Armonk, NY, USA).
Ethics, registration, funding, and potential conflicts of 
interest 
In accordance with Finnish regulations, informed patient 
consent was not required as the women were not contacted. 
Our study protocol went through the ethical evaluation of 
the National Institute for Health and Welfare to gain access 
to register data, permission number: THL/599/5.05.00/2010.
This study was funded by the Competitive Research funds of 
Pirkanmaa Hospital District, Tampere, Finland, representing 
governmental funding. The authors have no potential conflicts 
of interests to declare.
Results
1,989 women with 2,476 THRs were included in the study 
(Table 1). Of these, 111 (5.6%) women with 133 (5.4%) 
THRs had a delivery during the follow-up. The mean follow-
up in the delivery group was 9.3 years (0–21), and the median 
age at the start of the follow-up was 29 years. In the reference 
group, 1,878 women with 2,343 THRs had no deliveries. The 
mean follow-up was 8.1 years (0–21), and the median age at 
the start of the follow-up was 40.
RA was the most common indication for THR in both 
groups. It was, however, more prevalent in the delivery group 
(47%) than in the reference group (33%) (p = 0.001). Other 
chronic diseases were more common in the reference group. 
The distribution of THR fixation method or bearing type was 
similar between the groups. The delivery group had 51 revi-
sions, and 30 (59%) of the revisions were performed due to 
aseptic loosening. In the reference group, 645 THRs were 
revised, and 318 (49%) revisions were performed due to asep-
tic loosening.
The deliveries were analyzed and recorded per THR. 170 
deliveries occurred during the follow-up (mean of 1.3 deliver-
ies per THR). The maximum number of deliveries per patient 
during the follow-up was 5. Of the deliveries, 75 (44%) were 
vaginal and 95 (56%) Cesarean sections. 50 women with 
53 THRs had at least 1 vaginal delivery after THR and 61 
women with 80 THRs had only Cesarean sections after THR. 
The primary THR diagnoses and revision indications were 
similar in the vaginal delivery group and Cesarean section 
group (Table 2).
At 6 years, the survival rate in the delivery group was 91% 
(CI 85–96) and in the reference group 88% (CI 87–90). At 13 
Table 1. Background characteristics of the study population, types 
of hip prosthesis, and indications for revisions between the delivery 
group and the reference group. Values are frequency (%) unless 
otherwise specified
 Delivery group Reference group
Factor n = 133 n = 2,343
Age at primary THR a 29 (8) 40 (8)
Follow-up period (years) a 9.1 (6) 8.0 (8)
Rheumatoid arthritis 62 (47) 774 (33)
Other chronic disease b 5 (4) 208 (9)
Nulliparous at primary THR 78 (64) 778 (33)
Indication for THR  
 Inflammatory arthritis (RA + others) 62 (47) 731 (31)
 Primary osteoarthritis 12 (9) 532 (23)
 Secondary arthrosis 21 (16) 363 (16)
 DDH c 22 (17) 493 (21)
 Other 16 (12) 224 (10)
Metal-on-metal bearing 16 (12) 390 (17)
Type of primary THR fixation  
 Uncemented 114 (86) 1,859 (79)
 Hybrid 7 (5) 237 (10)
 Inverse hybrid 0 (0) 1 (0)
 Cemented 12 (9) 245 (10)
Revisions 51 (38) 645 (28)
Revision indications  
 Aseptic loosening 30 (59) 318 (50)
 Deep infection 1 (2) 11 (2)
 Periprosthetic fracture 0 (0) 12 (2)
 Dislocation 1 (2) 30 (5)
 Others 14 (27) 193 (30)
 Missing 5 (10) 81 (12)
a Median and interquartiles. 
b Includes: asthma, diabetes mellitus type 1, epilepsy, hypothyroid-
ism, hypertension, inflammatory bowel disease, major psychiatric 
disease. 
c DDH = developmental dysplasia of the hip.
Table 2. Comparison of primary diagnoses and revision indications 
in the delivery group between women with at least 1 vaginal deliv-
ery after total hip replacement (THR) with women with only Cesar-
ean sections after THR
 
 Vaginal delivery Cesarean section 
 after THR after THR
Factor n = 53 n = 80
Indication for THR   
 Inflammatory arthritis (RA + others) 19 43
 Primary osteoarthritis 4 8
 Secondary arthrosis 13 8
 DDH 10 12
 Other 7 9
Revisions 15 36
Revision indications:  
 Aseptic loosening 10 20
 Deep infection 1 0
 Dislocation 0 1
 Others 4 10
 Missing 0 5
DDH = developmental dysplasia of the hip.
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years, the survival rate was 50% (CI 39–62) for the delivery 
group and 61% (CI 59–64) for the reference group, respec-
tively (Figure 2, Table 3).
During the first time period (0 to 6.8 years’ follow-up), the 
adjusted Cox regression model showed no statistically signifi-
cant difference in the risk for revision between the delivery and 
the reference groups (adjusted HR 0.7, CI 0.4–1.2). During the 
later follow-up (6.8 to 21 years), there was still no difference in 
adjusted HR between the groups (HR 1.1, CI 0.8–1.6). 
Discussion
To our knowledge, our study is the first to assess THR implant 
survivorship in fertile-aged women in a large population-
based study sample. Based on our results, delivery does not 
seem to adversely affect hip implant survivorship after pri-
mary THR.
Our results are in concordance with previous smaller stud-
ies. In their study, Sierra et al. (2005) reported that delivery 
after primary THR does not decrease the survival rate of the 
implant. They had the largest number of participants prior to 
our study. 343 women with 420 THR were contacted and 47 of 
those had pregnancy ending in delivery. However, the survival 
rates for 5-, 10- and 15-year follow-up periods were calculated 
for the whole cohort with no comparisons made between the 
delivery and non-delivery groups. Our 6-year survival rate 
in both groups was in line with these results. Meldrum et al. 
(2003) had 13 hips with deliveries in their study population 
and reported no adverse effects for THR. Yazici et al. (2003) 
reported 21 THR patients with deliveries and no decrease in 
the survival rate of the THR. All these studies were retrospec-
tive with alternative response rates (30–75%). McDowell and 
Lachiewicz (2001) reported 5 women with 7 uncemented 
THRs having deliveries and, compared with matched refer-
ents, no differences between survival or hip functions were 
reported. Our study was the only one to report a slight but not 
statistically significant decrease in implant survival rate in the 
Kaplan–Meier analysis after delivery.
Cesarean section (CS) rate was markedly increased in the 
delivery group compared with overall CS rate in Finland. 
There have been previous reports in which women with dys-
plastic hips have been discussed to have smaller pelvic diam-
eters and therefore could tend to have CS (Sierra et al. 2005; 
Stea et al. 2007). Developmental dysplasia of the hip was an 
equally common indication for THR in women who only had 
Cesarean sections after THR as in those who delivered vagi-
nally after THR in our study. Also, revision indications did 
not differ between them. The reason for the very high CS rate 
in the delivery group remains unknown. We can only specu-
late that the presence of THR may have affected the patients’ 
and/or the physicians’ choice of delivery. However, it did not 
have any effect on THR survival rates.
Age was the only statistically significant variable that nega-
tively affected THR implant survivorship. The delivery group’s 
median age at the start of the follow-up was 29 years compared 
with the reference group’s 40 years. Previously, only Sierra et 
al. (2005) have applied the Cox regression model to analyze 
implant survivorship after delivery. In their model, delivery 
seemed to decrease THR survivorship, but once age at the time 
of primary THR was taken as part of the model, no further differ-
ences between the delivery group and the reference group were 
obtained. Previous non-delivery-related THR survival studies 
have reported similar findings of weaker implant survivorship in 
younger patients (Dorr et al. 1994, Nam et al. 2016, Tsukanaka et 
al. 2016). In particular, very young patients under 30 years have 
been reported to have had decreased THR survivorship (Mohad-
des et al. 2019) probably because of higher activity levels (Dorr 
et al. 1994, Adelani et al. 2013). Our survival rates were slightly 
lower compared with the recent study of Mohaddes et al. (2019), 
in which the 15-year THR survival rate for patients aged under 30 
at the time of THR was 76%. 
In young patients (< 50 years or less), indications for THR 
differ in comparison with older patients (+50 years). In 
younger patients, inflammatory arthritis and developmental 
hip diseases are more common, and primary osteoarthritis is 
Table 3. Kaplan–Meier 6- and 13-year survival rates with 95% confi-
dence intervals (CI) of primary total hip replacement of fertile-aged 
women aged 15 to 45 years at the time of THR
 K–M survivorship K–M survivorship
 at 6 years at 13 years
 No. of No. of  No. at survival No. at survival
Delivery hips revisions risk % (CI) risk % (CI)
Yes 133 51 100 91 (85–96) 22 50 (39–62)
No 2,343 645 1,411 88 (87–90) 456 62 (59–64)
Figure 2. Kaplan–Meier survival curves (with 95% confidence inter-
vals) of primary total hip replacement (THR) among fertile-aged 
women aged 15 to 45 years at the time of THR having 1 or more 
deliveries after THR (delivery group) compared with no deliveries after 
THR (reference group).
100
80
60
40
20
0
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rare (Adelani et al. 2013). Developmental dysplasia of the hip 
decreases the survival of the hip prosthesis in young patients 
(Havelin et al. 2000, Tsukanaka et al. 2016). There have been 
controversial results regarding the survival of the THR in 
RA patients. Some studies have suggested decreased THR 
survivorship, more common radiographic findings indicat-
ing implant failure, poorer function, and increased mortality 
among patients with RA (Creighton et al. 1998, Havelin et al. 
2000, Tang and Chiu 2001, Singh and Lewallen 2013, Good-
man et al. 2014, Schrama et al. 2015). Inflammatory arthritis 
as primary diagnosis for THR may also increase revisions due 
to deep infections (Dale et al. 2012). Previous large national 
cohort studies, however, have shown no decrease in THR 
survival due to RA (Havelin et al. 2000 , Furnes et al. 2001, 
Eskelinen et al. 2006). Because of the high prevalence of RA 
among young patients, it was taken as part of the Cox model. 
In our model, RA did not decrease THR survival. Indeed, it 
seemed patients with RA had better results during the first 
follow-up period (< 6.8 years). A similar finding was seen in 
a previous THR and delivery study, where Serra et al. (2005) 
found no decrease in the survival of hips operated due to an 
RA diagnosis in their step-by-step Cox results. 
The main strength of our study is the register-based design. 
Previous THR survival studies after delivery have been retro-
spective cohorts with questionnaires. Our design eliminates 
possible recall bias and has better completeness because revi-
sion indications are also reported to the Finnish Arthroplasty 
Register. In addition, we had by far the largest study popula-
tion with the longest follow-up, and our results are nationwide 
instead of from one hospital district catchment area. In addi-
tion, we were also able to combine information from several 
nationwide registers on patients’ long-term diseases and preg-
nancies. 
The first limitation of our study is the lack of patient-reported 
outcome measurements (PROMs), which forced our study to 
focus strictly on the survival of the implant. However, absence 
of PROM data does not affect our interpretation of the survival 
results. The second limitation was the study period. Our study 
period was from 1987 to 2007. Even though the implants used 
today differ greatly from those implanted 30 years ago, contem-
porary implant designs were used in the latter half of the study 
period, and this approach also enabled us to assess long-term 
implant survivorship in this rare cohort of patients.
In conclusion, based on the findings in this nationwide study 
offering hip replacement to fertile females, delivery does not 
seem to decrease THR implant survivorship. Women should 
not be afraid of or avoid becoming pregnant after THR.
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